What type of study is this?

September 10, 2025BMC OphthalmologyOpen Access

Protective effects of pituitary adenylate cyclase-activating peptide (PACAP) on high glucose-induced damage in human corneal epithelial cell

View Full Paper

Ask AI

Bookmark

PACAP38 treatment significantly restores cell proliferation and migration impaired by high glucose levels.
Compared to high glucose conditions, PACAP38 enhanced expression of Ki-67 and Bcl-2 in human corneal epithelial cells.
The mechanisms revealed that PACAP38 activated AMPK/ERK signaling pathways, promoting cell survival under hyperglycemic conditions.
Findings support PACAP38's role as a therapeutic candidate for managing diabetic keratopathy and its associated complications.

Discussion

No takes yet. Share an insight, caveat, or question.

Implication

Observational analysis shows that PACAP38 enhances cell viability and migration in human corneal epithelial cells, suggesting potential therapeutic benefits for diabetic keratopathy.

Cite This Study

Bao et al. (2025) studied this question.

synapsesocial.com/papers/68c1c64554b1d3bfb60f28bc https://doi.org/10.1186/s12886-025-04309-z

View Full Paper

Ask AI

Bookmark

Implication

Observational analysis shows that PACAP38 enhances cell viability and migration in human corneal epithelial cells, suggesting potential therapeutic benefits for diabetic keratopathy.

Protective effects of pituitary adenylate cyclase-activating peptide (PACAP) on high glucose-induced damage in human corneal epithelial cell

Key Points

Discussion

Implication

Cite This Study

Protective effects of pituitary adenylate cyclase-activating peptide (PACAP) on high glucose-induced damage in human corneal epithelial cell

Key Points

Discussion

Implication

Cite This Study

Also Consider

Also Consider